MORE than 100,000 patients worldwide, including those in Cuba, have benefited from Heberprot-P, a medication developed by Cuban biotechnology to treat diabetic foot ulcers, with excellent results.
Doctor of Sciences Manuel Raíces, PhD, a specialist in Genetic Engineering and Biotechnology, in conjunction with Havana’s Angiology and Vascular Surgery Institute, developed this leading product, and explained that the treatment had made amputation unnecessary in the majority of cases, hence improving quality of life, the AIN national news agency reported.
He announced that it is anticipated that a further 60,000 patients will benefit from Heberprot-P this year, with Cubans as a priority.
Amelia González, director of the Heberprot-P diabetic foot ulcer program in western Cuba, stated that between March 28 and April 5, Havana is to host the last stage of the Ecos workshop project from March 28-April 5, a project which began in the eastern province of Guantánamo on March 11.
Directed at family doctors, the workshops have been organized to update professionals on the application of the medication and inform them of the main results of the product in Cuba and overseas.
Heberprot-P continues to be the only product of its kind in the world and constitutes another achievement of Cuban biotechnology at the service of humankind.
Primary health care clinics have been established as part of the national program’s broad strategy to adopt an integral treatment approach using the medication for patients with diabetic foot ulcers.
In these clinics patients are assessed by a multidisciplinary team and can be treated with Heberprot-P if it is deemed necessary, González commented.